Palliative radiotherapy and symptom control

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Palliative radiotherapy uses ionising treatment to reduce a local symptom or prevent a local catastrophe. The referral should state one or more concrete goals: walk with less femoral pain, stop vaginal bleeding, reduce a chest-wall mass, protect cord function or control a dominant brain lesion. A vague referral for widespread progression makes target selection impossible and can impose travel without a measurable benefit.

Emergency sequencing is crucial. Radiation cannot stabilise an imminently failing femur on the day of treatment and cannot evacuate acute cord compression as rapidly as suitable surgery. Similarly, major bleeding may need embolisation and transfusion before radiation produces haemostasis. Clinical oncology, surgery, interventional radiology and acute oncology decide the sequence from physiology, mechanics, tumour sensitivity, prognosis and patient preference.

Fractionation balances convenience, durability and normal-tissue effect. A single 8 Gy fraction provides pain relief equivalent to longer schedules for uncomplicated bone metastasis, although retreatment is somewhat more frequent. A five- or ten-fraction course may serve postoperative beds, selected soft-tissue extension or nearby sensitive organs. Stereotactic treatment delivers high conformality for selected limited targets but requires greater planning precision and is not automatically kinder or quicker.

Benefit is delayed. Bone pain can flare transiently and then improve over days to weeks. Bleeding and compression may respond at different speeds. Acute reactions match the tissues in the field and can peak after the last fraction. Follow-up therefore needs a rescue plan, an expected response window and an alternative if the symptom does not improve. Prior plans and dose distributions must be retrieved before retreatment because cumulative normal-tissue tolerance, not elapsed time alone, determines safety.

Key points

Palliative radiotherapy is local treatment for a defined symptom or threatened structure; it does not treat every site of metastatic disease simultaneously.
Common indications include uncomplicated painful bone metastasis, selected MSCC, brain metastasis, tumour bleeding, painful soft-tissue mass, airway or venous compression and skin ulceration.
First-line assessment defines the exact symptom, anatomical target, emergency, expected survival, performance, previous radiation, systemic options, travel burden and patient goal.
Radiotherapy must not delay decompression, fixation, embolisation, endoscopy or airway control when mechanical or physiological rescue is faster and time critical.
For uncomplicated painful bone metastasis, a single 8 Gy fraction is an evidence-based first-line schedule for many adults and reduces travel without reducing the chance of pain relief.
A multifraction schedule such as 20 Gy in 5 fractions or 30 Gy in 10 may be selected for postoperative fields, selected cord or neurological disease, large soft-tissue components, retreatment constraints or longer local-control goals.
For MSCC with neurological signs, give dexamethasone 16 mg immediately and arrange whole-spine MRI within 24 hours; surgery and stability assessment precedes selection of urgent radiation.
NICE advises 8 Gy single-fraction radiotherapy for many nonsurgical MSCC cases unless side-effect risk makes a multifraction course more appropriate.
Stereotactic radiosurgery is preferred over whole-brain radiation for selected limited brain metastases; lesion volume, location, symptoms, systemic control and prognosis determine selection.
Haemostatic radiotherapy can reduce bleeding from lung, bladder, pelvic, gastrointestinal or fungating tumours, but major active haemorrhage still needs resuscitation and immediate source control.
Planning CT in the reproducible treatment position is the reference geometric study; diagnostic CT, MRI or PET is fused when it improves target definition.
Pain relief usually begins after several days and may continue improving for four to six weeks; continue background and rescue analgesia during the response interval.
Explain acute toxicity by field, not by the word radiation: thorax may cause oesophagitis, abdomen nausea, pelvis diarrhoea or cystitis and brain treatment fatigue or oedema.
Document dose, fractionation, field and organs exposed permanently because future surgery and re-irradiation depend on cumulative biological dose.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Painful local tumour

Bone destruction, periosteal stretch, soft-tissue infiltration and nerve compression create a discrete anatomical target whose shrinkage can reduce nociceptive and neuropathic input.

Bleeding tumour surface

Friable vascular tumour in lung, bladder, rectum, cervix, skin or another organ can ooze or bleed repeatedly despite local packing and systemic support.

Compression and obstruction

Epidural, airway, venous, oesophageal, biliary or pelvic mass can narrow a critical structure, although some sites require faster mechanical decompression first.

Intracranial or oligometastatic burden

Brain metastases and selected limited deposits can receive stereotactic or conventional treatment for neurological control within a broader systemic and prognostic plan.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Ionising radiation damages DNA
Direct ionisation and free radicals create lethal chromosome damage, with tumour cells dying during later division rather than disappearing at beam delivery.
2
Tumour shrinkage relieves the generator
Reduced cellular mass, inflammatory signalling, vascularity and pressure can improve pain, bleeding and compression over days to weeks after treatment.
3
Fractionation changes biological effect
A single larger fraction maximises convenience and equivalent pain palliation in selected settings, while smaller repeated fractions can protect nearby normal tissue or improve durable control.
4
Normal tissue defines the limit
Skin, mucosa, bowel, marrow, lung, brain, nerve and previously treated organs have dose-volume tolerance that shapes field, fraction size and retreatment feasibility.
5
Inflammation can briefly worsen symptoms
Cytokine release and oedema may produce pain flare or neurological swelling before tumour regression, requiring anticipatory analgesic or corticosteroid planning.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Uncomplicated painful bone target

Focal metastatic bone pain without fracture risk, cord compression or major soft-tissue extension is well suited to a short evidence-based schedule.

Mechanical pain needing stabilisation

Severe pain on weight bearing, turning or limb use with cortical destruction indicates structural risk and requires surgical assessment before radiation alone.

Haemostatic target

Recurrent visible or internal tumour bleeding after immediate stabilisation can respond to a short local course planned around nearby mucosa and organs.

Neurological emergencyRed flag

Weakness, sensory or sphincter change, falling consciousness or posterior-fossa pressure needs urgent imaging, steroid when indicated and decompression assessment.

Expected acute field effect

Erythema, fatigue, nausea, odynophagia, diarrhoea or cystitis arises only when the corresponding normal tissue receives clinically relevant dose.

Unexpected severe deteriorationRed flag

Fever, peritonism, shock, new major hypoxia or rapidly progressive neurological loss is not routine toxicity and requires emergency reassessment.

Red flags requiring action

Back pain with weakness, gait change, sensory loss or bladder or bowel dysfunction requires the MSCC emergency pathway before a routine radiotherapy referral.
A painful lytic long-bone lesion with functional pain, extensive cortical destruction or inability to weight bear needs orthopaedic stabilisation assessment before radiation alone.
Falling consciousness, pupillary asymmetry, seizure or rapidly progressive focal deficit requires emergency CT, corticosteroid for tumour oedema and neurosurgical review.
Stridor, rapidly worsening facial or neck swelling, hypoxia or inability to lie flat demands immediate airway and superior-vena-cava assessment before simulation.
Haemodynamic bleeding, haematemesis, major haemoptysis or rapidly falling haemoglobin requires resuscitation, transfusion and endoscopic, surgical or embolisation control while radiation is considered.
Severe focal pain, fever, peritonism or sepsis during radiation is not routine acute toxicity and requires infection, perforation or obstruction evaluation.
A previous irradiated field, implanted cardiac device, possible pregnancy or inability to reproduce treatment position requires early physics and specialist planning, not omission from the referral.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line symptom, function and goal assessmentFirst stepFirst line
Why
Define the target, mechanism, severity, emergency, performance, prognosis, previous local treatment and outcome the patient values.
Interpretation and limitations
A measurable goal and plausible target justify treatment; multifactorial fatigue or diffuse pain without a dominant site may not improve from local radiation.
02
Cause-directed diagnostic imaging
Why
Use radiography, CT, contrast MRI or PET to distinguish tumour from fracture, instability, infection, obstruction, haemorrhage or treatment effect.
Interpretation and limitations
Whole-spine MRI is the reference standard for suspected MSCC, while CT defines cortical failure and contrast MRI maps brain or neural targets.
03
Reference planning CT with immobilisation
Why
Create the treatment geometry for contouring target and organs at risk in a position that can be reproduced at delivery.
Interpretation and limitations
Fuse diagnostic MRI or PET when useful, but ensure registration accuracy; major pain, weight or organ-filling change may require a new plan.
04
Previous-radiation dose reconstruction
Why
Retrieve field, fractionation and dose-volume exposure before re-irradiation or treatment near a previously irradiated organ.
Interpretation and limitations
Calculate cumulative biological effect and account for interval and tissue recovery; a verbal history of prior radiation is insufficient for a high-risk overlap.
05
Blood and organ baseline
Why
Check FBC, renal, liver and electrolyte status when marrow field, bleeding, systemic combination, dehydration or medicine dosing makes them relevant.
Interpretation and limitations
Correct severe anaemia, infection and dehydration and plan concurrent systemic interruption; laboratory normality does not make an unstable fracture safe.
06
On-treatment image guidance
Why
Confirm patient and target position before each fraction according to technique and detect anatomical change that invalidates the plan.
Interpretation and limitations
Repeated setup correction, tumour shrinkage, fluid change or weight loss prompts clinical and physics review rather than normalising systematic error.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Mechanical instability needing surgery

An impending long-bone fracture or unstable vertebral segment will not become immediately load bearing after radiation and may require fixation or decompression first.

Infection or inflammatory toxicity

Osteomyelitis, abscess, pneumonia, colitis and immune treatment injury can mimic progressive tumour symptoms and may worsen if treatment delays antibiotics or immunosuppression.

Non-malignant pain or bleeding

Degenerative pain, ulcer disease, anticoagulation, haemorrhoids and vascular lesions need cause-directed treatment when imaging and examination do not support an irradiable tumour target.

Systemic or procedural alternative

Targeted drugs, endocrine treatment, surgery, embolisation, stent, ablation or drainage may work faster, more durably or with less burden for a particular symptom.

Treatment effect or recurrence

After previous radiation, fibrosis, fracture, radionecrosis and inflammatory change can mimic progression and require dose-map review and selected tissue or advanced imaging.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Urgent referralStabilise first and select the fastest effective sequenceFirst stepTumour causes neurological loss, airway compromise, unstable bone, major bleeding or obstructed organ.

1Use ABCDE care and activate MSCC, intracranial, airway, haemorrhage or fracture pathway with corticosteroid, transfusion, immobilisation or decompression as indicated.
2Obtain the time-critical imaging and joint surgical, interventional and radiation review, deciding whether an operation, embolisation, stent or drain must precede radiation.
3Simulate and deliver the shortest evidence-based radiation schedule compatible with anatomy and recovery, with a written rescue and toxicity plan.

02Painful bone metastasisSeparate uncomplicated pain from mechanical failureA focal metastatic bone site causes pain and radiation is being considered.

1Examine pain at rest and loading, neurological function and fracture risk and obtain radiograph, CT or MRI sufficient to exclude cord compression and impending failure.
2First lineUse a single 8 Gy fraction first line for uncomplicated pain, or select a longer course when postoperative, neurological, soft-tissue or durable-control factors justify it.
3Continue analgesia and mobility protection, explain possible flare and assess response over four to six weeks before considering re-irradiation or another diagnosis.

03Bleeding or compressive massControl physiology while radiation response developsA local tumour causes recurrent bleeding, venous, airway, oesophageal, urinary or pelvic pressure without an immediate surgical-only indication.

1Stabilise haemoglobin, airway, organ drainage and infection and use endoscopy, embolisation, stent or surgery when immediate mechanical control is required.
2Define a compact target and select fractionation from site, radiosensitivity, prior treatment, expected survival and travel burden rather than using one haemostatic schedule universally.
3AlternativeMonitor bleeding, obstruction and field toxicity during the response window and provide an alternative plan if physiology worsens before regression.

04After treatmentJudge benefit at the right time and preserve dose historyA palliative course is completed or symptoms persist after the expected response interval.

1Explain when field reaction peaks and when pain, bleeding or pressure should improve, continuing rescue analgesia, antiemetic, skin, mouth, bowel and nutrition support.
2Assess the original patient-valued goal at the indication-specific time and image sooner for red flags or non-mechanical deterioration.
3Archive plan and dose, and for non-response distinguish wrong target, progression, fracture, infection and treatment effect before specialist retreatment calculation.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Reduces oedema around compressed cord or cauda equina during urgent imaging and definitive decompression or radiation planning.

Dexamethasone for neurological MSCC

Give dexamethasone 16 mg orally immediately, or equivalent parenterally, when neurological symptoms or signs suggest MSCC, then 16 mg daily while surgery or radiotherapy is awaited and taper after definitive treatment starts.

Monitor glucose, infection, mood, proximal weakness and gastrointestinal risk; stop if MSCC is excluded and seek specialist advice before steroid in unconfirmed lymphoma without neurological signs.

Maintains mobility and sleep while tumour response develops and treats the temporary inflammatory increase that can follow bone radiation.

Analgesic cover for radiation response and flare

Continue the established regular non-opioid and opioid schedule with immediate-release rescue matched to current 24-hour exposure; some services use a short dexamethasone course for high bone-pain-flare risk.

Do not sedate mechanical instability into unsafe loading; monitor bowel, alertness, renal function and steroid effects and reduce analgesia only after sustained response.

Prevents 5-HT3-mediated nausea from upper-abdominal, craniospinal or other emetogenic fields and supports completion of a short course.

Ondansetron for emetogenic fields

For adult radiation-induced nausea, use the local site-specific prophylactic schedule, commonly ondansetron 8 mg orally one to two hours before an emetogenic abdominal fraction with later dosing only as protocol requires.

Review QT and electrolyte risk, constipation, hepatic impairment and serotonergic combinations and reassess obstruction or intracranial disease when vomiting is disproportionate.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Acute field toxicity

Skin reaction, fatigue, nausea, mucositis, oesophagitis, diarrhoea, cystitis and marrow suppression follow the tissues exposed and often peak after treatment ends.

Pain flare and oedema

Transient increased bone pain or swelling around brain and cord lesions can occur before response and may require planned rescue analgesia or corticosteroid.

Late tissue injury

Fibrosis, stricture, fracture, radionecrosis, neuropathy, endocrine loss and organ dysfunction may emerge months or years later, particularly after longer survival or retreatment.

Travel and treatment burden

Repeated attendance, immobilisation, ambulance transfer and waiting can consume limited energy and time, sometimes outweighing small incremental control benefit.

Non-response or early recurrence

Radioresistant biology, wrong symptom attribution, inadequate target coverage or rapid progression can leave symptoms unchanged and require reassessment rather than automatic re-irradiation.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

During urgent treatment, repeat neurological, airway, bleeding and pain assessment and escalate deterioration before the next scheduled fraction.
At each attendance verify identity, site, consent, position and image guidance and review whether anatomy, weight or fluid change still matches the plan.
Track the target symptom with a functional outcome, such as weight bearing, transfusion need, swallowing, cough or time out of bed, not imaging alone.
Monitor field-specific skin, mouth, oesophagus, nausea, bowel, bladder, marrow and neurological toxicity and explain that some effects peak after completion.
Review analgesic and corticosteroid dose, bowel function, glucose, infection and sleep and provide a written taper or escalation plan.
Assess pain response over several weeks after bone treatment; image immediately for new mechanical pain or neurological change rather than waiting for routine follow-up.
Preserve target, dose, fractionation, technique and organ-at-risk exposure in a durable record for any future surgery or re-irradiation.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

A short course is not lesser care

For uncomplicated bone pain, one evidence-based fraction can provide the same chance of relief while returning several days to the patient.

Radiation works after delivery

Tumour cells die and inflammation settles over time, so same-day non-response is expected and requires interim analgesia rather than declaring failure.

Mechanics outruns radiobiology

A femur at imminent fracture or an unstable spine may fail before radiation produces recalcification, making surgical review a first step.

Bleeding needs two clocks

Resuscitation and embolisation can act within minutes or hours, while haemostatic radiation acts over days; safe care plans for both timescales.

Field predicts side effects

Radiation is not systemically toxic by default: normal tissue inside the planned volume determines nausea, mucositis, diarrhoea and marrow effect.

Previous dose never disappears

Time permits some recovery but not a reset, so re-irradiation depends on old geometry and cumulative tissue-specific biological dose.

11Common pitfallsFrequent interpretation and management errors.

01
Referring diffuse pain without identifying a dominant anatomical target or functional goal.
02
Delaying cord, airway, fracture or haemorrhage rescue while waiting for routine radiotherapy planning.
03
Using a multifraction course automatically when one 8 Gy fraction provides equivalent uncomplicated bone-pain relief.
04
Giving radiation alone to an imminently failing long bone.
05
Assuming every brain metastasis requires whole-brain treatment instead of assessing focal options and prognosis.
06
Stopping analgesia on treatment day before radiation has had time to work.
07
Calling fever, peritonism or severe neurological decline an expected radiation reaction.
08
Choosing a schedule without considering transport and time burden.
09
Re-irradiating without retrieving the previous plan and cumulative dose.
10
Judging benefit from scan change while ignoring the symptom and function that justified treatment.